CN104758926B - 用于主动免疫治疗的Th1接种疫苗引发 - Google Patents
用于主动免疫治疗的Th1接种疫苗引发 Download PDFInfo
- Publication number
- CN104758926B CN104758926B CN201510137976.8A CN201510137976A CN104758926B CN 104758926 B CN104758926 B CN 104758926B CN 201510137976 A CN201510137976 A CN 201510137976A CN 104758926 B CN104758926 B CN 104758926B
- Authority
- CN
- China
- Prior art keywords
- cell
- mouse
- bcl1
- cells
- allogeneic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 30
- 229960005486 vaccine Drugs 0.000 title abstract description 50
- 230000036039 immunity Effects 0.000 title abstract description 32
- 238000011081 inoculation Methods 0.000 title description 33
- 201000010099 disease Diseases 0.000 claims abstract description 70
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 70
- 230000015654 memory Effects 0.000 claims abstract description 67
- 230000000735 allogeneic effect Effects 0.000 claims abstract description 58
- 239000000427 antigen Substances 0.000 claims abstract description 49
- 108091007433 antigens Proteins 0.000 claims abstract description 48
- 102000036639 antigens Human genes 0.000 claims abstract description 48
- 239000000203 mixture Substances 0.000 claims abstract description 47
- 210000004027 cell Anatomy 0.000 claims description 171
- 206010028980 Neoplasm Diseases 0.000 claims description 121
- 210000000447 Th1 cell Anatomy 0.000 claims description 43
- 201000011510 cancer Diseases 0.000 claims description 18
- 239000006166 lysate Substances 0.000 claims description 18
- 210000004881 tumor cell Anatomy 0.000 claims description 9
- 244000052769 pathogen Species 0.000 claims description 8
- 230000001717 pathogenic effect Effects 0.000 claims description 6
- 239000013592 cell lysate Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 97
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 86
- 101000980756 Homo sapiens G1/S-specific cyclin-D1 Proteins 0.000 description 86
- 230000004083 survival effect Effects 0.000 description 49
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 43
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 43
- 239000002671 adjuvant Substances 0.000 description 24
- 230000001225 therapeutic effect Effects 0.000 description 24
- 230000000977 initiatory effect Effects 0.000 description 22
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 19
- 238000004132 cross linking Methods 0.000 description 19
- 210000001744 T-lymphocyte Anatomy 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 238000002255 vaccination Methods 0.000 description 17
- 238000001994 activation Methods 0.000 description 16
- 108090000978 Interleukin-4 Proteins 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 15
- 230000004913 activation Effects 0.000 description 15
- 239000011049 pearl Substances 0.000 description 15
- 230000028993 immune response Effects 0.000 description 14
- 231100000518 lethal Toxicity 0.000 description 14
- 230000001665 lethal effect Effects 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 230000009885 systemic effect Effects 0.000 description 13
- 230000001960 triggered effect Effects 0.000 description 13
- 102100037850 Interferon gamma Human genes 0.000 description 12
- 108010074328 Interferon-gamma Proteins 0.000 description 12
- 230000008901 benefit Effects 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 108010029697 CD40 Ligand Proteins 0.000 description 10
- 102100032937 CD40 ligand Human genes 0.000 description 10
- 238000003306 harvesting Methods 0.000 description 10
- 210000000987 immune system Anatomy 0.000 description 10
- 210000004989 spleen cell Anatomy 0.000 description 10
- 230000008014 freezing Effects 0.000 description 9
- 238000007710 freezing Methods 0.000 description 9
- 239000012744 reinforcing agent Substances 0.000 description 9
- 238000011740 C57BL/6 mouse Methods 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 210000003462 vein Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 210000004970 cd4 cell Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 6
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 6
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 6
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 6
- 102100033467 L-selectin Human genes 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 208000035473 Communicable disease Diseases 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000010257 thawing Methods 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 230000000961 alloantigen Effects 0.000 description 4
- 230000002146 bilateral effect Effects 0.000 description 4
- 230000016396 cytokine production Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 102100032912 CD44 antigen Human genes 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- 230000004721 adaptive immunity Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 231100000636 lethal dose Toxicity 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000005934 immune activation Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000029069 type 2 immune response Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- -1 CD45RB Proteins 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 230000029662 T-helper 1 type immune response Effects 0.000 description 1
- 206010044684 Trismus Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 239000002102 nanobead Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 229940022511 therapeutic cancer vaccine Drugs 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10169208P | 2008-10-01 | 2008-10-01 | |
| US61/101,692 | 2008-10-01 | ||
| US12/570,442 US9695397B2 (en) | 2008-10-01 | 2009-09-30 | Th1 vaccination priming for active immunotherapy |
| US12/570,442 | 2009-09-30 | ||
| CN200980147749.6A CN102227224B (zh) | 2008-10-01 | 2009-10-01 | 用于主动免疫治疗的Th1接种疫苗引发 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980147749.6A Division CN102227224B (zh) | 2008-10-01 | 2009-10-01 | 用于主动免疫治疗的Th1接种疫苗引发 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104758926A CN104758926A (zh) | 2015-07-08 |
| CN104758926B true CN104758926B (zh) | 2017-09-22 |
Family
ID=42074205
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510137976.8A Active CN104758926B (zh) | 2008-10-01 | 2009-10-01 | 用于主动免疫治疗的Th1接种疫苗引发 |
| CN200980147749.6A Active CN102227224B (zh) | 2008-10-01 | 2009-10-01 | 用于主动免疫治疗的Th1接种疫苗引发 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980147749.6A Active CN102227224B (zh) | 2008-10-01 | 2009-10-01 | 用于主动免疫治疗的Th1接种疫苗引发 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US9695397B2 (https=) |
| EP (1) | EP2334309B1 (https=) |
| JP (4) | JP6042065B2 (https=) |
| CN (2) | CN104758926B (https=) |
| CA (1) | CA2739255C (https=) |
| DK (1) | DK2334309T3 (https=) |
| ES (1) | ES2635516T3 (https=) |
| HU (1) | HUE034855T2 (https=) |
| IL (1) | IL212102A (https=) |
| PL (1) | PL2334309T3 (https=) |
| PT (1) | PT2334309T (https=) |
| WO (1) | WO2010039924A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12012502233A1 (en) * | 2010-04-13 | 2022-10-05 | Immunovative Therapies Ltd | Methods and compositions for inhibition of treg cells |
| SG10201908048QA (en) | 2014-01-08 | 2019-10-30 | Immunovative Therapies Ltd | Treatment of Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome |
| TWI714529B (zh) * | 2015-05-20 | 2021-01-01 | 以色列商梵提夫免疫療法公司 | 人類免疫缺乏病毒/後天性免疫缺乏症候群之治療 |
| US11564980B2 (en) | 2018-04-23 | 2023-01-31 | Nantcell, Inc. | Tumor treatment method with an individualized peptide vaccine |
| TWI905535B (zh) | 2018-04-23 | 2025-11-21 | 美商南特細胞公司 | 新抗原表位疫苗及免疫刺激組合物及方法 |
| US20250319132A1 (en) * | 2024-04-16 | 2025-10-16 | Mirror Biologics, Inc. | Methods and compositions for improving the immune response against viral pathogens |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003034820A1 (en) * | 2001-09-19 | 2003-05-01 | Valeocyte Therapies Llc | Th1 CELL ADOPTIVE IMMUNOTHERAPY |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6051237A (en) * | 1994-11-08 | 2000-04-18 | The Trustees Of The University Of Pennsylvania | Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
| US20080199495A1 (en) * | 1999-04-15 | 2008-08-21 | Monash University | Stimulation of thymus for vaccination development |
| US20020131960A1 (en) * | 2000-06-02 | 2002-09-19 | Michel Sadelain | Artificial antigen presenting cells and methods of use thereof |
| AU2001294834A1 (en) * | 2000-09-26 | 2002-04-08 | Beth Israel Deaconess Medical Center | Recombinant bcg vaccines for the prevention and treatment of cancer |
| US20070025958A1 (en) * | 2000-10-27 | 2007-02-01 | Hadden John W | Vaccine immunotherapy |
| JP2004536800A (ja) * | 2001-05-09 | 2004-12-09 | アルカベロ アクチェセルスカプ | Ｔｈ１／ｔｈ２比を変調することによりｔｈ１及びｔｈ２細胞関連疾患を予防又は治療するための医薬組成物 |
| US20040013649A1 (en) * | 2002-05-10 | 2004-01-22 | Inex Pharmaceuticals Corporation | Cancer vaccines and methods of using the same |
| US20040115224A1 (en) * | 2002-12-16 | 2004-06-17 | Tsuneya Ohno | Preparation and administration of hybrid cell vaccines for the prevention of cancer |
| NZ542134A (en) * | 2003-03-04 | 2009-06-26 | Alexion Pharma Inc | Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells |
| US7402431B2 (en) * | 2004-03-01 | 2008-07-22 | Immunovative Therapies, Ltd. | T-cell therapy formulation |
| US7435592B2 (en) * | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| CA2555714C (en) * | 2004-02-26 | 2013-12-03 | Immunovative Therapies, Ltd. | Methods for preparing t-cells for cell therapy |
| US7181931B2 (en) * | 2005-02-28 | 2007-02-27 | White Dennis M | Method and apparatus for fitting chain jewelry assembly on an individual |
| US7435692B2 (en) * | 2005-10-19 | 2008-10-14 | Tokyo Electron Limited | Gas jet reduction of iso-dense field thickness bias for gapfill process |
-
2009
- 2009-09-30 US US12/570,442 patent/US9695397B2/en active Active
- 2009-10-01 WO PCT/US2009/059177 patent/WO2010039924A2/en not_active Ceased
- 2009-10-01 DK DK09818495.5T patent/DK2334309T3/en active
- 2009-10-01 CN CN201510137976.8A patent/CN104758926B/zh active Active
- 2009-10-01 JP JP2011530213A patent/JP6042065B2/ja active Active
- 2009-10-01 HU HUE09818495A patent/HUE034855T2/en unknown
- 2009-10-01 PL PL09818495T patent/PL2334309T3/pl unknown
- 2009-10-01 PT PT98184955T patent/PT2334309T/pt unknown
- 2009-10-01 ES ES09818495.5T patent/ES2635516T3/es active Active
- 2009-10-01 EP EP09818495.5A patent/EP2334309B1/en active Active
- 2009-10-01 CA CA2739255A patent/CA2739255C/en active Active
- 2009-10-01 CN CN200980147749.6A patent/CN102227224B/zh active Active
-
2011
- 2011-04-03 IL IL212102A patent/IL212102A/en active IP Right Grant
-
2014
- 2014-04-28 JP JP2014092886A patent/JP2014139247A/ja not_active Withdrawn
-
2016
- 2016-03-01 JP JP2016038729A patent/JP2016104818A/ja not_active Withdrawn
-
2017
- 2017-06-22 US US15/630,592 patent/US10744158B2/en active Active
- 2017-06-22 US US15/630,581 patent/US20170290857A1/en not_active Abandoned
- 2017-11-02 JP JP2017212788A patent/JP6789913B2/ja active Active
-
2020
- 2020-07-14 US US16/928,884 patent/US11833173B2/en active Active
-
2023
- 2023-10-26 US US18/495,532 patent/US20240050480A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003034820A1 (en) * | 2001-09-19 | 2003-05-01 | Valeocyte Therapies Llc | Th1 CELL ADOPTIVE IMMUNOTHERAPY |
Non-Patent Citations (2)
| Title |
|---|
| allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia lymphoma;HAR-NOY M ET AL;《LEUKEMIA RESEARCH》;20081001;第33卷(第4期);第525-538页 * |
| CD3/CD28-COSTIMULATED T1 AND T2 SUBSETS:DIFFERENTIAL IN VIVO ALLOSENSITIZETION GENERATES DISTINCTGVT AND GVHD EFFECTS;JUNG U ET AL;《BLOOD,AMERICAN SOCIETY OF HEMATOLOGY》;20031101;第102卷(第9期);第3439-3446页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102227224A (zh) | 2011-10-26 |
| IL212102A0 (en) | 2011-06-30 |
| US20170290857A1 (en) | 2017-10-12 |
| CN102227224B (zh) | 2015-03-25 |
| US20170281743A1 (en) | 2017-10-05 |
| JP2012504638A (ja) | 2012-02-23 |
| PT2334309T (pt) | 2017-10-06 |
| DK2334309T3 (en) | 2017-07-17 |
| CA2739255A1 (en) | 2010-04-08 |
| US20100086561A1 (en) | 2010-04-08 |
| HK1211230A1 (en) | 2016-05-20 |
| JP2018016651A (ja) | 2018-02-01 |
| US20240050480A1 (en) | 2024-02-15 |
| US11833173B2 (en) | 2023-12-05 |
| CA2739255C (en) | 2019-04-02 |
| ES2635516T3 (es) | 2017-10-04 |
| HUE034855T2 (en) | 2018-03-28 |
| EP2334309B1 (en) | 2017-05-31 |
| EP2334309A4 (en) | 2013-01-09 |
| CN104758926A (zh) | 2015-07-08 |
| PL2334309T3 (pl) | 2017-11-30 |
| EP2334309A2 (en) | 2011-06-22 |
| US9695397B2 (en) | 2017-07-04 |
| US20200338127A1 (en) | 2020-10-29 |
| US10744158B2 (en) | 2020-08-18 |
| JP6042065B2 (ja) | 2016-12-14 |
| JP6789913B2 (ja) | 2020-11-25 |
| JP2016104818A (ja) | 2016-06-09 |
| WO2010039924A3 (en) | 2010-07-22 |
| JP2014139247A (ja) | 2014-07-31 |
| IL212102A (en) | 2016-06-30 |
| WO2010039924A2 (en) | 2010-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Old | Immunotherapy for cancer | |
| US20240050480A1 (en) | Th1 vaccination priming for active immunotherapy | |
| Mondovì et al. | Increased immunogenicity of Ehrlich ascites cells after heat treatment | |
| CN103800896A (zh) | 一种自体肿瘤疫苗的制备方法及其应用 | |
| CN109125347A (zh) | 使用树突细胞和由高静水压力杀死的肿瘤细胞对癌症进行主动细胞免疫治疗的手段和方法 | |
| CN107488235B (zh) | 一种新的增强型抗原联合多肽诱导肝癌特异性ctl细胞的制备及应用 | |
| JP5498792B2 (ja) | 切除的免疫療法 | |
| Har-Noy et al. | Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma | |
| US20110150934A1 (en) | Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer | |
| RU2457546C1 (ru) | Способ моделирования аденокарциномы толстой кишки человека | |
| HK1158499B (en) | Th1 vaccination priming for active immunotheraphy | |
| HK1158499A (en) | Th1 vaccination priming for active immunotheraphy | |
| EP1595546A1 (en) | Remedy for cancer | |
| CN108030916A (zh) | 防治肿瘤和/或慢性结核病的Th2免疫反应抑制剂及其应用 | |
| HK1211230B (en) | Th1 vaccination priming for active immunotheraphy | |
| Teramoto et al. | 987 DNA encoding a Pan-MHC class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy | |
| Pedersen et al. | 989 Identification of highly active, cancer specific promoters for use in targeted gene therapy of small cell lung cancer | |
| Sergeeva et al. | 988 Preventive vaccination of mice with human melanoma cells injected subcutaneously into encapsulated polyacrylamide gel | |
| Pandya et al. | 221. The Utilization of Capsid-Optimized Adeno-Associated Virus (AAV) Vectors for Cancer Immunotherapy | |
| HK1230951A1 (en) | Ablative immunotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1211230 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1211230 Country of ref document: HK |